Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.66 USD | -0.90% | +1.52% | -12.86% |
10/05 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
10/05 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.86% | 91.34B | |
+29.56% | 682B | |
+30.35% | 586B | |
-3.80% | 364B | |
+17.48% | 327B | |
+3.31% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.24% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating